



Review

MicroRNAs in cancer – from research to therapy

William C.S. Cho *

Department of Clinical Oncology, Queen Elizabeth Hospital, Room 1305, 13/F, Block R, 30 Gascoigne Road, Kowloon, Hong Kong SAR

ARTICLE INFO

Article history:

Received 3 October 2009

Received in revised form 7 November 2009

Accepted 11 November 2009

Available online 18 November 2009

Keywords:

Cancer

Locked nucleic acid

MicroRNA

Target gene

Therapy

ABSTRACT

MicroRNAs (miRNAs) regulate target gene expression through translation repression or mRNA degradation. These non-coding RNAs are emerging as important modulators in cellular pathways, and they appear to play a key role in tumorigenesis. With increasing understanding of the miRNA target genes and the cellular behaviors influenced by them, modulating the miRNA activities may provide exciting opportunities for cancer therapy. Here the latest findings of which genes are targeted by each miRNA are reviewed, with particular emphasis on the deciphering of their possible mechanisms and the potential of miRNA-based cancer therapeutics.

© 2009 Elsevier B.V. All rights reserved.

Contents

1. Introduction	209
2. MicroRNA targets for potential therapeutic application	212
2.1. Cyclins (D1, D2, E1, E2, G1) and cyclin-dependent kinase (CDK6)	212
2.2. Cyclin-dependent kinase inhibitors (p21, p27 and p57)	212
2.3. Tumor proteins (p53, p63 and p73)	212
2.4. E2F transcriptional activators (E2F1, E2F2 and E2F3)	213
2.5. Myc family of transcription factors (c-Myc and N-Myc) and Myc antagonist (MNT)	213
2.6. Zinc finger E-box binding homeobox genes (ZEB1 and ZEB2)	213
2.7. Forkhead box O transcription factors (FOXO1 and FOXO3)	213
2.8. Epidermal growth factor receptors (EGFR, HER2/neu and HER3)	213
2.9. Insulin-like growth factor receptor (IGF-1R) and insulin-like growth factor (IGF-2)	214
2.10. Estrogen receptors (ER α and ESR1)	214
2.11. Neoplastic transformation inhibitor programmed cell death 4 (PDCD4)	214
2.12. Bcl-2 gene family members (Bcl-2 and Mcl-1)	214
2.13. Kirsten rat sarcoma (KRAS) and Ras homolog gene family members (RhoA and RhoC)	215
3. Potential use of microRNAs in cancer therapy	215
4. Perspectives and challenges	215
References	215

1. Introduction

As microRNAs (miRNAs) involve in biological development, cell proliferation, differentiation and apoptosis, dysregulation of miRNAs appears to play a crucial role in cancer pathogenesis [1]. Recent

advances in omics technologies have enabled the identification of hundreds of human miRNAs, but most of their targets remain unknown [2]. Although the identification of miRNA targets proceeds at a fast pace, we still know little about their mechanisms of action and the pathways that miRNAs modulate [3]. Identifying miRNAs and their targets that are essential for cancer development and metastasis may provide exciting therapeutic opportunities. Here recent findings of which genes are targeted by each miRNA and the possible mechanisms through which miRNAs affect tumorigenesis are summarized (Fig. 1, Table 1).

* Tel.: +852 2958 5441; fax: +852 2958 5455.

E-mail address: chocs@ha.org.hk.




Fig. 1. Graphical annotation of the pathway showing the targets of different upregulated (solid line—) and downregulated (broken line---) microRNAs in cancer summarized in this review.

Download English Version:

<https://daneshyari.com/en/article/2101080>

Download Persian Version:

<https://daneshyari.com/article/2101080>

[Daneshyari.com](https://daneshyari.com)